Companies · Pharmaceuticals

Nimbus Discovery, LLC

CAMBRIDGE · Pharmaceuticals

Diligence memoA one-page analyst read on Nimbus Discovery, LLC — recommendation, valuation, rhythm, risks.
$5.0M
Total raised · real
2
Rounds
0.4×
Latest step-up
Top 59%
Sector rank · raised
Seed
Latest stage · inferred · Mon Feb 28 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Nimbus Discovery, LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.96× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era.
  • Within the normal band (96% of peer median) for its niche.
Dormant
  • Last raise 15.3 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Nimbus Discovery, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
16.2 yr record
Peak capital year was 2010 with $3.5M across 1 filings.
Market position
ahead of 42% of Pharmaceuticals peers
Capital scale is ahead of 42% of Pharmaceuticals peers; modeled value is above 45% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2010: $3.5M across 1 filings.
  • Largest single filing was $3.5M on 2010-04-15.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Nimbus Discovery, LLC is one of 1610 Pharmaceuticals companies tracked from CAMBRIDGE. By capital raised it ranks mid-pack (ahead of 42% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2010-04-15 Raised $3.5M (real) Modeled valuation $133M (est)$3.5M$133MSeed2010Seed · 2011-02-28 Raised $1.5M (real) Modeled valuation $57M (est)$1.5M$57MSeed2011+$1.5MCumulative $5.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.5M · 2010
Seed extension$1.5M · 2011

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$57.1M
Base estimate est.
$1.1M
Conservative case
$447.7M
Upside case
$7.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $133.1M · 2010-04-152010Seed · modeled $57.1M · 2011-02-282011
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
15.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$5.7M/yr
Capital velocity
16.2 yr
On record since
2010
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.6× of median
This company$5.0M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.9× of median
This company$1.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$57.1M
Sector median$76.1M

Raised more than 42% of sector peers (real $). Modeled value above 45% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #32 of 58.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)First China Pharmaceutical Group, Inc. · Seed Raised $6.8M · modeled $145.7M (est)MediQuest Holdings LLC · Seed Raised $4.7M · modeled $140.1M (est)Ampla Pharmaceuticals Inc · Seed Raised $5.4M · modeled $138.9M (est)Biomimetix Pharmaceutical, Inc. · Seed Raised $8.1M · modeled $125.5M (est)Prexa Pharmaceuticals Inc · Seed Raised $3.3M · modeled $123.9M (est)VIA Pharmaceuticals, Inc. · Seed Raised $4.5M · modeled $121.8M (est)iTherx Pharma, Inc. · Seed Raised $3.2M · modeled $120.7M (est)Crititech Inc · Seed Raised $6.0M · modeled $114.1M (est)Harbor BioSciences, Inc. · Seed Raised $2.8M · modeled $107.5M (est)iTherX Pharmaceuticals, Inc. · Seed Raised $2.8M · modeled $105.8M (est)Lotus Tissue Repair, Inc. · Seed Raised $2.8M · modeled $104.6M (est)CELLECTAR, Inc. · Seed Raised $2.7M · modeled $103.5M (est)Nimbus Discovery, LLC (this company) Raised $5.0M · modeled $57.1M (est)Nimbus Discovery, LLC
CompanyStageRaised · realValue · estvs peer med.
First China Pharmaceutical Group, Inc.Seed$6.8M$145.7M2.44×
MediQuest Holdings LLCSeed$4.7M$140.1M2.35×
Ampla Pharmaceuticals IncSeed$5.4M$138.9M2.33×
Biomimetix Pharmaceutical, Inc.Seed$8.1M$125.5M2.10×
Prexa Pharmaceuticals IncSeed$3.3M$123.9M2.08×
VIA Pharmaceuticals, Inc.Seed$4.5M$121.8M2.04×
iTherx Pharma, Inc.Seed$3.2M$120.7M2.02×
Crititech IncSeed$6.0M$114.1M1.91×
Harbor BioSciences, Inc.Seed$2.8M$107.5M1.80×
iTherX Pharmaceuticals, Inc.Seed$2.8M$105.8M1.77×
Lotus Tissue Repair, Inc.Seed$2.8M$104.6M1.75×
CELLECTAR, Inc.Seed$2.7M$103.5M1.73×
Nimbus Discovery, LLC this companySeed$5.0M$57.1M0.96×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.5M2010-04-15$17.5M$133.1M90%
Seed$1.5M2011-02-28$7.5M$57.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.5M2010-04-15
    • First recorded raise — entered as Seed.
  2. Seed$1.5M2011-02-28
    • Raised 10 mo later, in step with the ~13 mo sector norm.
    • Round 2.3× smaller than the prior — bridge or down round.
Intelligence
2012 ~Q1
Modeled next raise · ~10mo cadence
$1.5M
Modeled next size est.range $1.5M$2.4M
0.4×
Last step-up
$5.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Bruce Booth11 other2010-04
Vicki Sato5 other2010-04
Ramy Farid4 other2010-04
Registry & provenance

Nimbus Discovery, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1490403
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Generex Biotechnology CorpPharmaceuticalsSeed$4.8M$72.4Msame sector · same stage
Biscayne Pharmaceuticals Inc.PharmaceuticalsSeed$4.7M$23.2Msame sector · same stage
Sequel Pharmaceuticals IncPharmaceuticalsSeed$5.4M$38.0Msame sector · same stage
FGH Biotech, Inc.PharmaceuticalsSeed$4.6M$79.1Msame sector · same stage
DARA BioSciences, Inc.PharmaceuticalsSeed$4.6M$55.1Msame sector · same stage
iVeena Delivery Systems, Inc.PharmaceuticalsSeed$5.6M$81.0Msame sector · same stage
Biostar Pharmaceuticals, Inc.PharmaceuticalsSeed$5.7M$80.6Msame sector · same stage
Sarentis Therapeutics IncPharmaceuticalsSeed$4.4M$28.5Msame sector · same stage
Frequently asked
How much funding has Nimbus Discovery, LLC raised?
Nimbus Discovery, LLC has raised approximately $5.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Nimbus Discovery, LLC's estimated valuation?
Provath's modeled valuation for Nimbus Discovery, LLC is approximately $57.1M (modeled range $1.1M–$447.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Nimbus Discovery, LLC at?
Nimbus Discovery, LLC's latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Feb 28.
What does Nimbus Discovery, LLC do and where is it based?
Nimbus Discovery, LLC operates in the Pharmaceuticals sector, based in CAMBRIDGE.
Explore related

See where Nimbus Discovery, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Nimbus Discovery, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.